The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.from Moneycontrol Business News https://ift.tt/syN5ThD
Syngene to acquire plant from Stelis Biopharma for Rs 702 crore
The company has entered into a binding term sheet with Stelis to acquire its Bengaluru-based Unit 3 biologics manufacturing unit, Syngene said in a late night statement on Tuesday.from Moneycontrol Business News https://ift.tt/syN5ThD
ग्रामीण भागात जन्मालेला आहे आणि माझी बोली भाषा लिहीण्याचा प्रयत्न करतो य.,
Subscribe to:
Post Comments (Atom)
Start-up Street:Â Social justice and the start-up ecosystem
Disparities in start-ups are a global phenomenon and affirmative action is needed to ensure an equal opportunities environment for aspiring...
No comments:
Post a Comment